uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis
Show others and affiliations
2007 (English)In: Endocrine-Related Cancer, ISSN 1351-0088, Vol. 14, no 2, 433-444 p.Article in journal (Refereed) Published
Abstract [en]

Hereditary medullary thyroid carcinoma (MTC) is caused by germline mutations in the RET proto-oncogene, resulting in constitutive activation of the RET tyrosine kinase. A substantial proportion of sporadic MTCs also have RET mutations, making the RET tyrosine kinase a potential therapeutic target in MTC. We have established a transplantable MTC in nude mice from a sporadic human MTC carrying a RET C634R mutation. Transplanted tumors had an exponential growth rate with an approximate doubling time of about 3 weeks, and expressed a neuroendocrine phenotype characteristic of MTC, e.g., expression of calcitonin, chromogranin A (CgA), synaptophysin, synaptic vesicle protein 2 (SV2), vesicular monoamine transporter-1 and -2, carcinoembryonic antigen, cytokeratin 8/18, epithelial cadherin, and neural cell adhesion molecule. Plasma calcitonin and CgA levels were elevated in tumor-bearing mice and correlated with tumor size. Cytogenetic analysis, including spectral karyotyping, confirmed the human origin of the xenografted tumors and demonstrated an abnormal, near triploid karyotype. Treatment of tumor-bearing nude mice with the tyrosine kinase inhibitor ZD6474, which specifically inhibits RET, epidermal growth factor receptor (EGFR), and vascular endothelium growth factor receptor (VEGFR) tyrosine kinases, resulted in a dose-dependent inhibition of tumor growth. Oral ZD6474 given once daily (250 mg/kg, 5 days/week) reduced tumor volume to 11% when compared with controls after 4 weeks. Our results show that this transplantable MTC, designated GOT2, represents a novel and useful model for studies of MTC and RET tyrosine kinase-dependent tumor growth.

Place, publisher, year, edition, pages
2007. Vol. 14, no 2, 433-444 p.
Keyword [en]
Aged, Animals, Calcitonin/blood, Carcinoma; Medullary/*drug therapy/enzymology/pathology, Cell Line, Tumor, Cell Transformation, Neoplastic/drug effects, Chromogranin A/blood, Disease Models, Animal, Humans, Karyotyping, Male, Mice, Mice, Nude, Mutation, Piperidines/pharmacology, Protein Kinase Inhibitors/pharmacology, Protein-Tyrosine Kinases/antagonists & inhibitors/genetics/metabolism, Proto-Oncogene Proteins c-ret/*antagonists & inhibitors/genetics/metabolism, Quinazolines/pharmacology, Receptor, Epidermal Growth Factor/antagonists & inhibitors, Thyroid Neoplasms/*drug therapy/enzymology/pathology, Vascular Endothelial Growth Factor Receptor-1/antagonists & inhibitors, Xenograft Model Antitumor Assays
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-15955DOI: 10.1677/ERC-06-0033ISI: 000248720300021PubMedID: 17639056OAI: oai:DiVA.org:uu-15955DiVA: diva2:43726
Available from: 2008-03-26 Created: 2008-03-26 Last updated: 2011-02-01Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=17639056&dopt=Citation

Search in DiVA

By author/editor
Stridsberg, Mats
By organisation
Clinical Chemistry
In the same journal
Endocrine-Related Cancer
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 183 hits
ReferencesLink to record
Permanent link

Direct link